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29.1  Introduction
Photopatch testing combines the techniques of two 
subspecialties in Dermatology, patch testing for aller-
gic contact dermatitis and phototesting for photoder-
matology. Due to difficulties in having both technologies 
together (a patch test clinic and an UV irradiation 
source), or because photoallergic contact dermatitis is 
uncommon [1], this technique is not so widely per-
formed. In a survey by Lehmann in the beginning of 
2000, only a few dozens of clinics in Europe were per-
forming photopatch testing and only two centres tested 
more than 50 patients/year [2].
Also, in photopatch testing, apart from the inherent 
temporal and regional variability of skin reactivity, 
many variables have to be dealt with: allergen concen-
trations and vehicles, test series and reading of tests 
results from allergic contact dermatitis, UV source, 
UV spectrum, UV irradiance and UV dose reaching 
the skin from photodermatology, and, then, the com-
mon final interpretation of test results. Therefore, there 
has been some difficulty in standardizing procedures. 
But, photodermatologists and contact dermatologists 
met in Amsterdam, in 2002 and 2007, and agreed upon 
a consensus methodology, allergen series and interpre-
tation of test results [2]. Also, thereafter, several stud-
ies are being performed in order to strengthen and 
improve this consensus methodology [3–5].
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29.2  Indications for Performing 
Photopatch Tests
29.2.1  Main Indication
The primary indication for photopatch testing is to con-
firm a diagnosis of photoallergic contact eczema / pho-
toallergy and find the responsible allergen. It can also 
contribute to distinguish photoallergic from phototoxic 
reactions, although this is not always easy. This distinc-
tion may be important as photoallergic reactions are 
usually more severe, with increasing intensity on further 
exposures, with the possibility of progressing to persis-
tent photosensitivity and reactivity to cross- reactive 
chemicals. Therefore, recognizing and avoiding the 
allergen is crucial for the prognosis of the dermatitis.
Clinical manifestations of photosensitivity are very 
polymorphic, sometimes with difficulty in distinguish-
ing photoallergy from phototoxicity – acute or chronic 
eczema, urticarial, lichenoid and pigmented reactions, 
erythema multiforme, exaggerated sunburn, etc. (see 
Chap. 18 for details). In photosensitivity from systemic 
agents, lesions are usually localized on a symmetrical 
distribution, on the face, neck, V-area of the upper 
chest, forearms, back of the hands and legs, whereas in 
photoallergic contact dermatitis, lesions occur in the 
areas of concomitant application of a photosensitizer 
and UV exposure (Fig. 29.1a, b). But there are less 
obvious patterns of photoallergy: the eczematous reac-
tions, sometimes associated with targetoid lesions of 
erythema multiforme, can also involve some shaded 
areas [6]; the allergen may, inadvertently, be trans-
ported by hands to areas other than the one of primary 
application, as for ketoprofen (ectopic dermatitis) 
[6–8]; only part of the exposed skin may be involved, 
e.g. cheilitis as a manifestation of photoallergy from a 
systemic photosensitizer [9] or cheilitis and chin der-
matitis from a mouth wash containing benzydamine 
[10]; sometimes lesions spare the area of application 
and occur at a distance, as in the case of hand dermati-
tis from using a vaginal wash containing benzydamine 
[11] and connubial photoallergic contact dermatitis 
can also occur [7, 12, 13] (Fig. 29.1a, b).
Also, the relation to sunlight exposure may not be 
so evident for the patient, as most reactions do not 
occur immediately on sun exposure, some involve 
non-exposed areas or have an asymmetric distribution, 




Fig. 29.1 (a, b) Chronic 
photoallergic contact 
dermatitis from benzydamine 
contained in Momem gele®, 
which the patient applied 
regularly to his wife. The 
distribution of lesions is 
similar to systemic photosen-
sitivity, probably due to 
systemic transcutaneous 
absorption of the NSAID.  
(c) Positive photopatch tests 
to benzydamine at 1 and 5% 
pet. irradiated with 5 J/cm2  
of UVA and to the drugs 
containing the drug (Tantum 
verde® and Momem gele®) 
(right side), with negative 

















































329 Photopatch Testing 
29.2.2  Other Indications for Photopatch 
Testing
Apart from patients with suspected photoallergic con-
tact eczema / photoallergy, others can also benefit from 
this study, namely any patient with a dermatitis that 
mainly affects the exposed sites (Table 29.1).
Photopatch testing may be important to distinguish 
an airborne allergic contact dermatitis from photosen-
sitivity. Both involve the face, neck, V-area of the upper 
chest, dorsum of the hands, forearms and the legs, and 
even though shaded and hairy areas, e.g. upper eyelid, 
retroauricular folds and submandibular area, are clas-
sically spared in photosensitivity and involved in air-
borne dermatitis, this difference is not always so evident 
[7]. Also, photoallergic contact dermatitis can occur 
from an airborne allergen, as olaquindox, present in 
pig feeds [14].
Facial dermatitis, suspected to be cosmetic dermati-
tis, can be due to a photosensitizer in a cosmetic, e.g. 
UV filters, which are frequently responsible for aller-
gic and photoallergic contact dermatitis in cosmetics 
[15–18]. Facial, hair and nail cosmetics usually con-
tain UV filters, both to prevent photoaging and skin 
cancer in the users and also to photostabilize the prod-
uct and increase its shelf life.
UV filters, both in cosmetics and sunscreens, are 
the main cause of photoallergic contact dermatitis 
(Fig. 29.2a). Therefore, any suspicion of skin intolerance 
to a sunscreen deserves photopatch testing. Patients with 
idiopathic photodermatoses (chronic actinic dermatitis, 
polymorphic light eruption) or other types of chronic 
photosensitivity (photosensitive atopic dermatitis, lupus 
erythematosus) are particularly prone to develop photo-
allergic contact dermatitis from UV filters, as they 
have to use sunscreens daily to prevent photosensitivity 
[1, 16, 17]. Therefore, this is another indication to per-
form photopatch testing, most particularly when these 
patients present with an eczematous reaction or there is 
an unexpected cutaneous response to therapy.
When, in the investigation of photosensitivity, the 
patient refers exposure to a known phototoxic agent, 
particularly if it occurs with a slight sun exposure or 
little contact with the phototoxic substance, photopatch 
testing may also reveal photoallergy. Photoallergy to 
psoralens can develop during PUVA therapy or from 
contact with plants containing psoralens [19]. These 
patients react to very low concentrations of psoralen 
(down to 0.0001%) in the photopatch test [20] or, both 
in the patch and photopatch test, therefore, associating 
both allergic and photoallergic contact dermatitis 
[21, 22]. Also, for known phototoxic drugs like pro-
methazine, chlorpromazine, benzydamine, lomefloxa-
cin and tiaprofenic acid, cases of photoallergy have 
been diagnosed by photopatch testing [23, 24].
In patients with photosensitivity from systemic 
agents, particularly drugs, photopatch testing has shown 
to be positive in several instances [10, 25–27], namely 
for piroxicam [28–32], ketoprofen and carprofen [26], 
fenofibrate [10, 31], lomefloxacin (Fig. 29.3) [23, 24, 
33], ciprofloxacin [24], flutamide [34, 35], carbam-
azepine [27] and efavirenz [36], among others. Never-
theless, in this setting, photopatch tests are more 
frequently negative and the study has to proceed with 
other tests. Systemic photoprovocation (irradiation of a 
small area of the normal back skin with increasing doses 
of UVA (1–5 J/cm2) and/or UVB after drug intake) and 
the determination of the minimal erythema dose (MED) 
in UVB and UVA, before and after exposure to the drug, 
can be important to confirm the participation of the drug 




Any dermatitis predominant on exposed sites (suspected 
airborne dermatitis)
Facial dermatitis (suspected cosmetic dermatitis)
Skin intolerance to sunscreens
Idiopathic photodermatosis (chronic actinic dermatitis, 
polymorphic light eruption) or diseases with chronic 
photosensitivity (atopic dermatitis, lupus erythematosus), 
with worsening of photosensitivity or no response to 
adequate therapy
Systemic drug photosensitivity
Dermatitis suspected from a phototoxic substance, when 
occurring with a low UV dose and slight contact
Table 29.1 Indications for performing photopatch tests
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Even though all these are indications for photopatch 
testing, this procedure is not performed very frequently; 
therefore, it certainly is underused, both in Europe and 
in the rest of the world [2, 31]. This and, eventually, a 
wrong choice of photoallergens may explain the pre-
sumed low prevalence of photoallergy [1, 38]. But, in a 
recent Italian study, photoallergic contact dermatitis 
represented 10% of all photodermatosis [31], which 
probably means that this is not such a rare problem, at 
least in geographical areas with high sun exposure.
29.3  Photopatch Testing Technique
29.3.1  How to Perform Photopatch Tests
A standardized amount of the allergens, diluted on the 
most convenient vehicle, is applied on the chambers as 
for patch testing, e.g. 15, 20 and 25 PL for liquids, 
respectively in Finn Chambers® (Epitest Ltd Oy, 
Tuusula, Finland), van der Bend Chambers® (van der 
Bend, Brielle, the Netherlands) and large IQ chambers 
(Chemotechnique Diagnostics, Malmö, Sweden), and 
20 mg for petrolatum in 8 mm Finn Chambers®, which 
correspond to a string across the chamber or a small 
pile in the middle [39, 40]. For photopatch testing, two 
equal sets of allergens are prepared and applied on 
Fig. 29.3 Photoallergic reaction from oral lomefloxacin, with 
positive photopatch tests to lomefloxacin
a b
Fig. 29.2 Allergic and photoallergic contact dermatitis of the 
face from sunscreens (a), with positive patch tests to ethylhexyl 
methoxycinnamate (equal reaction score in the irradiated and 
non-irradiated areas), and positive photopatch tests to the other 
UV filters, namely butilmetoxydibenzoylmethane, PABA, iso-
amyl-p-metoxycinnamate, methylbenzyliden camphor and phe-
nylbenzimidazol sulphonic acid (1+ or 2+ reactions, only in the 
























529 Photopatch Testing 
symmetrical areas of the back, avoiding the central 
vertebral groove. Occlusion is best maintained for 
2 days, but the variation of results is not very signifi-
cant in case patches are removed after 1 day, the usual 
procedure in photodermatology units as it is the time 
to read photo tests performed simultaneously [3].
A first reading should be performed after removing 
the patches to detect contact reactions present before 
irradiation. Then, while one set is shield from light 
with a UV opaque material, the other is irradiated with 
5 J/cm2 of UVA.
A reading within 30 min after irradiation should be 
performed, in order to detect immediate urticarial 
reactions.
At least one other reading should be performed 2 or 
3 days after irradiation (D3/D4), to detect allergic and 
photoallergic reactions (Table 29.2).
29.3.2  When to Perform Photopatch Tests
Photopatch testing should be performed, whenever pos-
sible, when there are no active lesions. How long after 
their resolution is not known, but it is advised at least 
2 weeks after stopping a local or systemic steroid [2]. If it 
is not possible, at least the back has to be clear of lesions, 
but more false positive reactions can be expected.
As that for patch testing, it is not adequate to per-
form photopatch testing after sunburn or after an impor-
tant sun exposure on the back. The immunosuppressive 
effect of UV light is known for the sensitization phase 
of allergic contact dermatitis and although not so well 
studied, this effect may be extensive to the elicitation 
phase [41]. Therefore, due to transient modifications of 
the antigen presenting capacity of the skin induced by 
UV, it is probably advised to postpone the tests, for 3–4 
weeks, after sunburn.
29.3.3  Irradiation Source and UV Dose
The dose of 5 J/cm2 of UVA, tolerated by most indi-
viduals, including those with lower phototypes, is now 
consensual. Irradiation with 10 J/cm2, or more, is 
responsible for more phototoxic reactions and, although 
some photoallergic reactions occur after 1–2 J/cm2 of 
UVA, some false negatives might occur with this low 
UV dose [42].
There are several possible sources for UV irradia-
tion, as long as the spectrum is broad-band UVA (320–
400 nm), and a dose of 5 J/cm2 delivered at the skin 
surface can be adequately measured. Usually fluores-
cent UV lamps are used, like those used for PUVA 
therapy (both for whole body or hand and feet irradia-
tion). They emit a reproducible and stable-wide UVA 
spectrum and are easily accessible.
For regular photopatch testing monochromator is 
not adequate. Also, UVB lamps are not used on a regu-
lar basis. Most photopatch tests reactions occur also 
with UVA, even if the photoallergen absorbs mainly in 
UVB, as sulfonamides and diphenhydramine [7]. Only 
in exceptional cases UVB irradiation was needed to 
prove photosensitivity, like in a case of systemic pho-
tosensitivity from ambroxol [43]. But, probably, there 
Two accepted procedures, type A, used most frequently in contact dermatitis clinics and type B, mainly in photodermatology units
Reading 1 includes a reading before and another immediately after irradiation (a,b)
Reading 2 is optional. Its main interest is to distinguish crescendo from decrescendo reactions, considered respectively photoallergic 
and phototoxic
Reading 3 is the most important. It is usually performed at D4 (procedure A), but can be done either at D3 or D4 in procedure B
Reading 4 is optional, but could be interesting to detect late reactions and, also, to evaluate crescendo or decrescendo reactions
Procedure D0 D1 D2 D3 D4 D5/6




Reading 1 (a,b) Reading  
2 (optional)
Reading 3 Reading 4 
(optional)








Reading 3 Reading 3/4 Reading 4 
(optional)













































































are not enough data on the regular photopatch testing 
with UVB [44].
29.3.4  Photopatch Testing in Particular 
Cases (Immunosuppression  
and Photosensitivity)
It is usually advised not to test patients on immunosup-
pressive drugs, but it may not be possible to stop them, 
as in patients under immunosuppression for solid organ 
transplantation. Photopatch tests can be positive in this 
setting but, of course, more false negative reactions 
can be expected. If the patient is under transient treat-
ment with corticosteroids, it is advised to wait, at least, 
2 weeks after its suspension or to its reduction to a 
dose equivalent to10 mg prednisolone/day.
A similar problem may arise when photopatch test-
ing HIV-positive patients with severe immunosuppres-
sion. Nevertheless, these patients still develop contact 
hypersensitivity reactions [45] and patch and photo-
patch tests can be positive independent of the CD4 
count. In a recent case of efavirenz photosensitivity, 
photopatch tests were positive in a patient with a high 
number of circulating viral copies and with a very low 
CD4 cell count (56 CD4/PL) [36].
In these settings, a positive test can be validated, but 
no definite conclusion can be taken on negative photo-
patch tests.
When testing a UVA photosensitive patient, like a 
patient with chronic actinic dermatitis, it is better to 
evaluate the threshold of reactivity to UV beforehand, 
that is perform phototests to evaluate MED. Irradiation 
for the phototests can be done, on Day 0, simultaneous 
with the application of the patches. Then, after reading 
the phototests and determining the MED (Day1), 
choose only a dose of 50–75% of the MED for irradiat-
ing the photopatch tests. In the interpretation of the test 
results, more false positive results can be expected, as 
when testing patients with active lesions elsewhere.
29.4  Reading and Interpretation of Test 
Results
29.4.1  Timing of the Readings
Readings have, obligatorily, to be performed immedi-
ately before and after UV irradiation, and 2 or 3 days 
after the irradiation. Some variability on the timing of 
the readings is admitted and has to do with the occlu-
sion time and, consequently, the day of irradiation 
(procedure A and B – see Table 29.2).
After irradiation, it would be interesting to perform 
readings for 3 or more consecutive days, in order to 
evaluate the crescendo or decrescendo pattern inter-
preted, respectively, as a photoallergic or phototoxic 
pattern, but this is not practical. Moreover, this cre-
scendo/decrescendo pattern has been questioned and is 
not uniformly consistent with these two mechanisms 
of photosensitive reactions [46].
Readings performed before and immediately after 
UV irradiation (D1 or, preferably D2) are necessary, 
respectively, to record reactions present before irradia-
tion and those that appear immediately thereafter.
The most important obligatory reading for evaluat-
ing delayed photoallergic reactions is performed 2 or 
3 days after irradiation (D3, D4 or D5). This interval is 
necessary for the development of the T-cell-mediated 
hypersensitivity reaction to the new photoproduct 
formed during UV irradiation. In this reading, it is 
important to compare reactions in the irradiated and 
non-irradiated panel of allergens, to distinguish con-
tact allergy (positive in both sets) from photoallergy 
(positive only in the irradiated set) (Table 29.3). At this 
time, irradiated areas contiguous to those of allergen 
application are used as a control for evaluating skin 
reactivity to UVA with no allergen. Reaction in this 
control area may occur in chronic actinic dermatitis or 
another photosensitive dermatosis or if the patient is, 
inadvertently, taking a systemic photosensitive drug 
(amiodarone, chlorpormazine or thioridazine, fluorqu-
inolone, NSAID, fenofibrate, etc.).
29.4.2  Scoring of the Reactions
Reactions should be scored according to the International 
Contact Dermatitis Research Group (ICDRG), as 
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729 Photopatch Testing 
“−” (negative), “+?” (doubtful, only with faint ery-
thema), “+” to “+++” (faint to strongly positive reac-
tions, namely with erythema, infiltration and possibly 
papules for 1+, erythema, infiltration, papules and pos-
sibly vesicles for 2+ and erythema, infiltration and 
coalescent vesicles or a bulla for 3+), “IR” (irritant), 
and NT (not tested) [2].
29.4.3  Interpretation of Test Results: 
Allergy or Photoallergy
A photopatch test is positive when it occurs only in the 
irradiated set of allergens. When 2+ or 3+ reactions are 
observed interpretation is easy, but a doubtful or weak 
1+ reaction occurring only in the irradiated area can be 
more difficult to interpret. It can be due to the addi-
tional effect of UV irradiation on a subclinical allergic 
or irritant patch test [4].
When reading immediately after irradiation, an urti-
carial reaction to an allergen exclusively in the irradi-
ated area can be due to immediate hypersensitivity, as in 
photoallergic contact urticaria, which has been described 
with oxybenzone [47] and chlorpromazine [48].
A transient macular erythema that regresses within 
24 h, sometimes with residual hyperpigmentation, 
attributed to phototoxicity, occurs very occasionally 
with NSAIDs (benoxaprofen and tiaprofenic acid), 
promethazine and some UV filters [5, 46, 49, 50].
When reading 1 or more days after irradiation, if an 
allergen reacts on both sets of tests, with a similar 
intensity, this is contact dermatitis, allergic or irritant. 
Probably, at D2, when removing the patches, this reac-
tion was already present (Fig. 29.2b).
When a reaction, graded as 1+ to 3+, occurs only in 
the irradiated set of allergens it is a positive photopatch 
test (Fig. 29.1c and 29.2b). A simple observation does 
not discriminate definitively between a phototoxic and 
a photoallergic reaction. In a phototoxic reaction, the 
test is usually more uniform, with erythema, some-
times with infiltration and with sharp limits, and tends 
to regress more quickly (peak intensity by 24 h), and 
this reaction occurs in a high percentage of individuals 
tested under the same circumstances. A typical photo-
allergic reaction is more pruritic, with papules or vesi-
cles, which sometimes goes beyond the strict area of 
contact with the allergen, and tends to increase in 
intensity with a peak in 48 or 72 h after irradiation. 
Another argument to support photoallergy is the absence 
of this reaction in control patients and maintenance of 
the positive reaction with serial dilutions of the aller-
gen and with lower UV doses of irradiation. Spongiotic 
dermatitis with no sunburn cells, on histology, also 
suggests photoallergy.
Other combinations of reactions can occur, namely 
negative reactions on both sides, irritant reactions 
on both sides, eventually with photo-augmentation 




bThe meaning of this type of reaction is not completely understood
Reading 1 Reading 2 Reading 3a Test results Interpretation of 
positive reactionsNo UV UVA No UV UVA No UV UVA
− − − + to +++ − + to +++ + Photopatch test Photoallergy or 
phototoxicity
+ + ++ ++ ++ ++ + Patch test Contact allergy






++ ++ ++ − or + ++ − or + Photo-inhibitionb
Table 29.3 Interpretation of photopatch test results
Core Message
A photopatch test is positive when the reaction  ›
to the allergen occurs only in the irradiated set 
of allergens. Most often, on a single reading,  
it is not possible to distinguish definitively 







































































a  photo-augmented or photo-aggravated allergic con-
tact reaction or a photo-inhibited or photo-suppressed 
allergic contact reaction (Table 29.3).
By definition, a photo-aggravated allergic contact 
reaction is considered when, in the irradiated set, it is 
graded with at least one “+” more than in the non- 
irradiated site. This can occur with contact allergens that 
also have some photoactive potential, like etofenamate, 
ketoprofen, UV filters and perfumes [7]. It can represent 
the association of allergic and photoallergic contact der-
matitis or a photo-augmentation of contact allergy [4].
Photo-inhibition or photo-suppression, with reduc-
tion in the intensity or complete suppression of an aller-
gic contact reaction on the irradiated site, is seldom 
observed. This may not be relevant or it can be due to 
UV-induced immunosuppression or variability of the 
cutaneous response in different areas of the back [4].
Also, in the interpretation of the results, it is impor-
tant to have in mind a possible technical error, namely 
with inadvertent UV exposure in the set of allergens 
that was supposed to be shielded.
29.4.4  Relevance of Positive Reactions
To determine reaction relevance, a good detailed ques-
tionnaire with recent and past history has to be done very 
carefully with the patient. Positive reactions may explain 
the present dermatitis (current relevance) or be due to a 
past exposure, with or without lesions, representing past 
or old relevance or, simply, previous exposure [2].
Also, it is important to know that many photoaller-
gens cross-react with contact allergens or other photo-
allergens, which can explain some positive reactions. 
Photoallergy to ketoprofen is associated with positive 
photopatch tests to other NSAIDs of the arylpropionic 
acid group that share the benzophenone moiety (tiapro-
fenic acid and suprofen), to benzophenone UV filters, 
mostly oxybenzone, and to the lipid lowering drug, 
fenofibrate [6, 8]. More frequently, these patients also 
have positive photopatch tests to fentichlor [51] and 
positive patch tests to balsam of Peru and fragrance 
mix I, probably due to the similarity to cinnamic alde-
hyde [52]. Fluorquinolones can cross-react within the 
group (lomefloxacin, ciprofloxacin) [23], like the phe-
nothiazines used as neuroleptics (chloropromazine and 
thioridazine), topical antihistamines (promethazine) or 
muscle relaxants (chlorproethazine) [53]. Positive 
photopatch tests to piroxicam occur in patients with 
previous contact allergy to thiomersal and its moiety 
thiosalicylic acid [10, 54]. Therefore, in the rare situa-
tions of a negative photopatch test to piroxicam and a 
very typical history of photoallergic contact dermatitis 
or systemic photoallergy from this drug, a positive 
patch test to thiosalicylic acid (0.1% pet.) can be a good 
indication that piroxicam was responsible [32, 55].
29.5  Allergens for Photopatch Testing 
(Basic and Additional Series)
The allergens used in photopatch testing are very dif-
ferent from centre to centre, but there is usually a com-
mon group of allergens responsible for most positive 
reactions. Therefore, for detecting the most common 
allergens and comparing results among centres, a rec-
ommended basic list of photoallergens should be used 
for regular photopatch testing [2], with the additions 
of regionally prevalent allergens [10, 16, 31, 56, 57] 
(Table 29.4).
A photoallergen basic tray of allergens has to be 
dynamic and subject to temporal changes (additions and 
removals). Along the last decades, the main allergens 
responsible for photoallergic contact dermatitis were 
identified and removed from the market, therefore, they 
became “historical” photoallergens and, for the moment, 
they have no place in a basic tray of photoallergens. 
These are musk ambrette, prohibited in perfumes, the 
UVA filter isopropyl-dibenzoylmethane, withdrawn in 
1994, the antibiotic olaquindox, a swine feed additive 
banned, in 1998, by the European Commission [14], 
and the halogenated salicylanylides, removed from 
disinfectants and hygiene products in most countries, 
since 1976.
On the other hand, as new UV filters have been 
introduced in the market – Mexoryl SX (terephtalydene 
Core Message
The recommended Basic tray of allergens for  ›
photopatch testing has to be dynamic. At present, 
it is recommended to include UV filters and some 
NSAIDs, namely ketoprofen. Regional additions 


















































































929 Photopatch Testing 
Table 29.4 Allergens for photopatch testing, to be included in a basic tray (*) and in an extended tray for photopatch testing, 
according to geographical variations (+) and for aimed testing
INCI/INN CAS Vehicle
UV filters
*Butyl methoxydibenzoylmethane/avobenzone 70356-09-1 10% pet.
*Benzophenone-3/oxybenzone 131-57-7 10% pet.
*Benzophenone-4/sulisobenzone 4065-45-6 2% pet.
*Ethylhexyl methoxycinnamate 71617-10-2 10% pet.
*Isoamyl-p-methoxycinnamate 71617-10-2 10% pet
*PABA/aminobenzoic acid 150-13-0 10% pet.
*Octyl dimethyl PABA 21245-02-3 10% pet.
*4-methylbenzylidene camphor 27503-81-7 10% pet.
*Phenylbenzimidazole sulfonic acid 27503-81-7 10% pet.
+Benzophenone-10/mexenone 1641-17-4 10% pet.
+Homosalate 8045-71-4 5% pet.
+Octyl salicylate/2-ethylhexyl salicylate 118-60-5 10% pet.
+Octocrylene/ethyl-hexyl-cyano-diphenylacrylate 6197-30-4 10% pet.
+Octyltriazone/ethylhexyl triazone 88122-99-0 10% pet.
+Drometrizole trisiloxane (Mexoryl XL) 155633-54-8 10% pet.
Terepthalylidene dicamphor sulphonic acid (Mexoryl SX)a 92761-26-7 10% H20
Bis-ethylhexyloxyphenol methoxyphenol triazine (Tinosorb S)a 187393-00-6 10% pet.
Methylene-bis-benzotriazolyl tetramethylbutylphenol(Tinosorb M)a 103597-45-1 10% pet.
Diethylamino hydroxybenzoyl hexyl benzoate (Uvinul A Plus)a 302776-68-7 10% pet.
Disodium phenyl dibenzimidazole tetrasulfonate(NeoheliopanAP)a 180898-37-7 10% pet.
Diethylhexyl butamido triazone (Uvasorb HEB)a 154702-15-5 10% pet.
Drugs
*Ketoprofen 22161-86-0 1% pet.
+Diclofenac sodium 15307-79-6 5% pet.
+Ibuprofen 15687-27-1 5% pet.
+Naproxen 22204-53-1 5% pet.
+Etofenamate 30544-47-9 2% pet.
+Piroxicam 36322-90-4 1% pet.
+Benzydamine 642-72-8 1-5% pet.
+Chlorpromazine 50-53-3 0.1% pet.
+Promethazine 60-87-7 0.1% pet.
Other allergens
Fentichlor 97-24-5 1% pet.










































dicamphor sulfonic acid), Tinosorb M (methylene- bis-
benzotriazolyl tetramethylbutylphenol), Tinosorb S (bis-
ethylhexyloxyphenol methoxyphenyl triazine), Uvinul 
A Plus (diethylamino hydroxybenzoyl hexyl benzoate), 
Neoheliopan AP (disodium phenyl dibenzimidazole 
tetrasulfonate) and Uvasorb HEB (diethylhexyl but-
amido triazone), it may be adequate to add some of 
these molecules to a photopatch test tray [5], even 
though they are more photostable and, for the moment, 
there are no or very few references to contact dermatitis 
[58, 59].
29.5.1  UV Filters in the Basic and 
Additional Tray for Photopatch 
Testing
In most studies, including those from outside Europe 
[60, 61], UV filters are the most frequent photoaller-
gens. In European studies they were responsible for 
5.6–80% of the positive photopatch tests or photo-
aggravated reactions and, when considering all patients 
tested, positive photopatch reactions to UV filters 
occurred in 5.7–21.8% [10, 15, 16, 31, 56, 57, 62]. 
Therefore, UV filters have to be the main constituents 
of a photoallergen series [2, 16], even though, which 
ones can be a subject of discussion. It is consensual to 
include, in a basic series, the following UV filters: the 
benzophenones, oxybenzone and sulizobenzone, the 
dibenzoylmethane, butyl methoxydibenzoylmethane, 
the cinnamates, isoamyl-p-methoxycinnamate and eth-
ylhexyl methoxycinnamate, p-aminobenzoic acid and 
its analogue, octyl-dimethylPABA, 4-methylbenzylidene 
camphor and phenylbenzimidazole sulfonic acid. The 
recommended concentration for testing these molecules 
is 10% pet. (equal to the maximum allowed concentra-
tion for most UV filters in sunscreens), except for ben-
zophenone 4/sulizobenzone for which 2% pet. is advised 
[5]. Other UV filters that have been responsible for pho-
toallergic reactions can be tested in an extended series, 
namely mexenone (benzophenone 10), octocrylene, 
drometrizole trisiloxane, homosalate, ethylhexyl 
salicilate and ethyl hexyl triazone [56, 63–65]. At pres-
ent, the newer UV filters are being, prospectively, evalu-
ated in an European multicentre photopatch study to 
decide, whether or not, to include in a photopatch test 
tray. (Table 29.4)
29.5.2  Drugs in the Basic and Additional 
Tray for Photopatch Testing
With the wide use of topical NSAIDs and their fre-
quent responsibility in cases of photoallergic contact 
INCI international nomenclature of cosmetic ingredients; INN international nonproprietary names; CAS chemical abstracts service
aNew UV filters that may be included in a photopatch test series, mainly for research purposes
Table 29.4 (continued)
INCI/INN CAS Vehicle
Hexachlorophene 70-30-4 1% pet.
6-Methylcoumarin 92-48-8 1% pet.
Quinine sulphate 6119-70-6 1% pet.
Diphenhydramine 58-73-1 1% pet.
“Historical” photoallergens
Tetrachlorosalicylanilide/benzamide 1154-59-2 0.1% pet.
Tribromosalicylanilide/tribromsalan 1322-38-9 1% pet.
5-Bromochlorosalicylanilide 3679-64-9 1% pet.
Triclocarban 101-20-2 1% pet.
Olaquindox 23696-28-8 1% pet.
Musk ambrette 83-66-9 5% pet.
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dermatitis, some of them quite severe, it is also manda-
tory to include some of these molecules in a basic pho-
topatch test series. The most important candidate is 
ketoprofen [2, 6, 8, 66, 67], which is the most frequent 
photoallergen in recent Italian, French and Spanish 
studies [31, 56, 57] and also quite frequent in Belgium 
and Sweden [6, 66]. Other NSAIDs, recently proposed 
to be included in the basic series, as naproxen, diclofenac 
and ibuprofen [2], are not so frequently responsible for 
photoallergy.
Apart from a basic series, recommended for all 
photopatch tests, regionally prevalent allergens should 
be added adequately [10, 16, 31, 56, 57]. This is the 
example of drugs used more frequently in some coun-
tries where they are responsible for a large number of 
photoallergic reactions, namely the NSAID piroxicam, 
used both topically and by systemic administration, in 
Portugal, Spain and Italy [10, 31, 57], benzydamine, 
used as a topical NSAID or a mouth or vaginal wash, 
in Portugal and Spain [10, 12, 57], the topical antihis-
tamine, promethazine, widely used in Portugal and 
Greece [10, 68] or its analogue chlorproethazine, used 
in France as a muscle relaxant [53, 56] or the neuro-
leptic chlorpromazine that can induce photoallergic 
contact dermatitis in health care workers or relatives 
of patients who smash the pills before administration 
[10, 69].
29.5.3  Other Allergens for Photopatch 
Testing
Also, we must take into account the “historical” pho-
tosensitizers. Some are not available anymore, like 
musk ambrette and isopropyl-dibenzoylmethane, and, 
therefore, it is not probable that new cases of photoal-
lergy are diagnosed. On the other hand, other “histori-
cal” photoallergens, like olaquindox and halogenated 
salicylanilides, are still used in countries outside 
Europe, and some “imported” products can be respon-
sible for new cases of photoallergy [14]. Occasional 
relevant reactions are still found with other haloge-
nated antimicrobials, like fentichlor and bithionol 
[31, 70], but they occur more often in patients with 
photoallergy from other causes, like that from keto-
profen [51, 66]. The photosensitizer, 6-methylcumarin, 
an ingredient of perfumes not allowed in Europe, was 
recently responsible for facial pigmentation in a patient 
from Thailand [71]. PABA, which was frequently 
responsible for photoallergic contact dermatitis in the 
60s and therefore was almost completely removed 
from sunscreens, was responsible for a recent case of 
photoallergic contact dermatitis from a sunscreen mar-
ket in the UK until recently [72]. Therefore, these his-
torical allergens can still be used in aimed photopatch 
testing.
Also, it is important to photopatch test patient’s own 
products, namely cosmetics, sunscreens, drugs or occu-
pational material. New or hidden photoallergens may 
be discovered in these products. Even though there is 
an increased concern on pretesting the phototoxic/pho-
toallergic potential of new cosmetics, UV filters and 
drugs before the introduction in the market, there is 
always the chance of finding a new photoallergen.
29.6  Conclusions
Although there is still some variation in the procedures 
and, particularly, in allergens used for photopatch test-
ing, we are nearer to standardization which will allow 
a more regular use of this procedure and comparison of 
results between centres. As we have shown, the tech-
nique is not so difficult to perform and probably many 
more patients, than those with typical photoallergic 
contact dermatitis, can benefit from it.
It is important to publish regularly the results of 
multicentre studies to know the more prevalent photo-
allergens and cross-reactive substances in order to take 
measures to reduce their expression in the market, as 
has occurred with the “historical” photoallergens. 
Local or regional studies are also important to adapt 
photopatch test trays to the population that is the object 
of the study.
If we perform this technique more often, under 
standardized procedures, we may, probably, get to the 
conclusion that photoallergy and, particularly, photo-
allergic contact dermatitis, is not so uncommon.
Core Message
It can be important to photopatch test with  ›
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